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T-cell immunoglobulin domain and mucin domain-containing molecule-3 (Tim-3) was
up-regulated on viral specific T cells and contributed to T cells exhaustion during chronic
hepatitis B virus (HBV) infection. However, modulation of Tim-3 expression was still
not fully elucidated. To evaluate the potential viral and inflammatory factors involved
in the inductor of Tim-3 expression on T cells, 76 patients with chronic HBV infection
(including 40 chronic hepatitis B [CHB] and 36 asymptomatic HBV carriers [AsC]) and
40 of normal controls (NCs) were enrolled in this study. Tim-3 expressions on CD4+
and CD8+ T cells were assessed in response to HBV-encoding antigens, HBV peptide
pools, and common γ-chain (γc) cytokines stimulation by flow cytometry. HBV peptides
and anti-CD3/CD28 directly induced Tim-3 expression on T cells. γc cytokines also
drive Tim-3 up-regulations on both CD4+ and CD8+ T cells in patients with chronic
HBV infection. However, γc cytokines did not enhance the Tim-3 inductions by either
anti-CD3/CD28 or HBV peptides stimulation. Furthermore, γc cytokines-mediated Tim-3
induction could not be abrogated by γc cytokine receptor-neutralizing antibodies. The
current results suggested that elevation of Tim-3 expression on T cells could be regulated
by both antigen-dependent and -independent manner in patients with chronic HBV
infection. The role of γc cytokines in modulation of inhibitory pathway might be evaluated
as immunotherapies in humans.
Keywords: hepatitis B virus, T-cell immunoglobulin domain and mucin domain-containing molecule-3, T cell
receptor, common γ-chain cytokines, immunomodulation
INTRODUCTION
Hepatitis B virus (HBV) leads to a chronic infection in 10% of adults and 90% of children, which
results in 1∼2 million people died annually worldwide due to HBV-related end-stage liver diseases,
such as liver cirrhosis, hepatic failure, and hepatocellular carcinoma (Hoofnagle et al., 2007; Lok
and McMahon, 2009; Lu and Zhuang, 2009). The outcome of hepatitis B is closely linked to
their immune status to mediate the clearance of virus. Interferon-γ (IFN-γ) production by viral
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specific CD4+ and CD8+ T cells response is pivotal for
controlling acute hepatitis B virus infection (Rehermann et al.,
1995; Bertoletti and Naoumov, 2003). In contrast, the inability of
T cells results in the collapse of HBV-specific adaptive immune
response in chronic hepatitis B (CHB) (Bertoletti and Naoumov,
2003; Chisari et al., 2010). More importantly, chronic HBV
infection is not directly associated with liver inflammation,
which is the results of interaction between virus and host
immune response. Chronic HBV infection could be divided
into different phases (Lian et al., 2014). Immune tolerant phase
is characterized by high HBV DNA and normal ALT, which
showed as asymmetric HBV carriers, while CHB patients reveal
acute increase in ALT and continuing hepatic injury (Lian et al.,
2014). However, the precise mechanisms corresponding to T cells
tolerance and immune evasion in chronic HBV infection are still
not fully elucidated.
Recent studies revealed that multiple inhibitory immune
regulatory proteins, including programmed death-1 (PD-
1), cytotoxic T-lymphocyte antigen-4 (CTLA-4), and T-cell
immunoglobulin domain and mucin domain-containing
molecule-3 (Tim-3), were involved in the modulation of T cells
impairment during chronic infections (Seddiki et al., 2014;
Pauken and Wherry, 2015a,b). Tim-3 could be expressed on
several cell types in immune system, including CD4+ and CD8+
T cells (Monney et al., 2002; Hastings et al., 2009; Dorfman
et al., 2010). The role of Tim-3 could be vary depending on
contexts where it was expressed (Gorman and Colgan, 2014).
Study on tuberculosis infection provided evidence that Tim-3
promoted both CD4+ and CD8+ T cell responses (Qiu et al.,
2012). However, Tim-3 was found to strongly suppress the
T cells functions and was associated with T cells impairment
or exhaustion in autoimmune diseases (Lee and Goverman,
2013) and chronic microbial infections (Jones et al., 2008;
Sehrawat et al., 2009; Moorman et al., 2012; Gorman et al.,
2014). Furthermore, Tim-3 contributed to T cell exhaustion
partly by enhancing T cell receptor (TCR)-signaling pathway
(Wherry, 2011; Ferris et al., 2014), while TCR was also an
essential component of Tim-3 elevation based on the finding
that CD3/CD28 costimulation up-regulated Tim-3 expression
on CD4+ T cells (Hastings et al., 2009).
Overexpression of Tim-3 contributed to HBV persistence
by induction of T cells dysfunction (Li et al., 2012; Nebbia
et al., 2012), inhibition of viral-specific CD8+ T cells (Ju
et al., 2009; Wu et al., 2012), and suppression of natural
killer cells (Ju et al., 2010). However, the role of elevated
Tim-3 on T cells in chronic HBV infection was still poorly
understood. Human immunodeficiency virus (HIV)-1 protein
Nef directly induced PD-1 expression, which was another
exhaustionmarker (Muthumani et al., 2008).Moreover, common
γ-chain (γc) cytokines also induced Tim-3 expression in an
antigen-independent manner in HIV-1 infection (Mujib et al.,
2012). Thus, we hypothesized that soluble viral and inflammatory
factors may be involved in the inductor of Tim-3 expression
on T cells. To test this possibility, Tim-3 expressions on CD4+
and CD8+ T cells were examined in response to HBV antigens,
peptides, or γc cytokines stimulation. The synergic effects of these
factors were also evaluated by costimulation.
METHODS
Subjects
A total of 76 hepatitis B e antigen (HBeAg)-positive
HBV-infected patients, including 40 CHB patients and 36
asymptomatic HBV carriers (AsC), were enrolled in this study.
The diagnoses were made according to the diagnostic standard
of Chinese Guideline of Prevention and Treatment for Chronic
Hepatitis B (2010 version). All patients were hospitalized or
followed-up in Tangdu Hospital from March 2011 to July 2014.
No patients were co-infected with HIV, other hepatitis viruses,
or concurrently aﬄicted by autoimmune diseases. Patients who
previously received anti-HBV agents or immunomodulatory
treatments were also excluded. For normal controls (NCs),
Forty healthy individuals with matched age and sex were also
enrolled. The clinical data obtained for the enrolled subjects
are listed in Table 1. The study protocol was approved by the
ethics committee of Tangdu Hospital, Fourth Military Medical
University, and written informed consent was obtained from
each subject.
Virological and Biochemical Assessments
HBV DNA was quantified using a commercial real-time PCR kit
(PG Biotech, Shenzhen, China) with a detection limitation of 2
log10 copies/mL. Hepatitis B surface antigen (HBsAg), anti-HBs,
HBeAg, anti-HBe, anti-hepatitis core antigen were quantified
using the ARCHITECTHBsAg, anti-HBs, HBeAg, anti-HBe, and
anti-HBc reagent kit (Abbott GmbH & Co. KG, Wiesbaden,
Germany). Serum biochemical assessments were made using
an automatic analyzer (Hitachi 7170A, Hitachi Ltd, Tokyo,
Japan).
Peripheral Blood Mononuclear Cells
(PBMCs) Isolation and Stimulation
PBMCs were isolated by Ficoll-Hypaque (Sigma-Aldrich, St.
Louis, MO) density gradient centrifugation. PBMCs were
cultured at 1 × 106/mL in RPMI 1640 (Invitrogen Gibco,
Grand Island, NY, USA) supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Invitrogen Gibco). PBMCs from CHB
and AsC were stimulated with either the mixture of HBV
antigens [including HBsAg (AbDSerotec, Oxford, UK; final
concentration 5 µg/mL), HBeAg (Abcam, Cambridge, MA,
USA; final concentration10 µg/mL), and HBcAg (AbDSerotec;
final concentration1 µg/mL)] or the mixture of HBV full-
genome peptides pool (15 amino acids of each peptide with
5 amino acids overlapping, final concentration 10 µg/mL) for
4 days. In some experiments, PBMCs were also co-cultured
with either common γc receptor cytokines (IL-2, IL-7, IL-15,
or IL-21, respectively, Peprotech Inc, Rocky Hill, NJ, USA;
final concentration 25 ng/mL), anti-CD3/CD28 (eBiosciences,
San Diego, CA, USA; final concentration 1 µg/mL), or anti-
common γc receptor neutralizing antibody (R&D System,
Minneapolis, MN, USA; final concentration 10 µg/mL) for 4
days. The concentrations of the antigens, peptides, cytokines,
and neutralizing antibody were reported previously (Zhang et al.,
2010, 2014; Mujib et al., 2012; Zhao et al., 2015; Wei et al.,
2016).
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TABLE 1 | Clinical characteristics of enrolled subjects.
NC AsC CHB
Case (n) 40 36 40
Age (years) 24.52 ± 4.02 25.52 ± 3.09 26.15 ± 2.18
Male gender (%) 62.50% (25/40) 52.78% (19/36) 67.50% (27/40)
HBV DNA (log10 IU/mL) N.A. 4.53 ± 1.70 4.01 ± 1.95
ALT (U/L) 15.26 ± 3.11 23.54 ± 5.51 87.00 ± 24.35
NC, normal controls; AsC, asymptomatic HBV carrier; CHB, chronic hepatitis B; N.A., not
applicable. Data were presented as mean ± SD.
Flow Cytometry
Anti-CD3-APC (BD Bioscience, San Jose, CA, USA), anti-CD4-
FITC (BD Bioscience), anti-CD8-PE-Cy7 (BD Bioscience), and
anti-Tim-3-PerCP-Cy5.5 (R&D System) were used for surface
staining. In some experiments, anti-phosphorylated STAT1 (p-
STAT1)-Alex Flour 647 (pY701) (BD Bioscience) was also used
for intracellular staining. Samples were analyzed with a BD
FACS Aria II analyzer (BD Biosciences). Acquisitions were
performed with CellQuest Pro software (BD Biosciences) and
analyses were performed with FlowJo version 7.6.2 for Windows
(Tree Star Inc., Ashland, OR, USA). Isotype control antibodies
were used to separate positive and negative cells in the Alex
Flour 647, APC, FITC, PE-Cy7, and PerCP-Cy5.5 fluorescence
channels.
Statistical Analysis
Data were analyzed using Graphpad Prism version 5.0
(GraphPad Software, La Jolla, CA, USA). The Kruskal-
Wallis H test and Dunn’s multiple comparison test were
used for comparison among groups. The Mann-Whitney
test was used for comparison between two groups. A
value of P < 0.05 was considered to indicate a significant
difference.
RESULTS
HBV Peptides Directly Induced Tim-3
Expression on T Cells
We firstly analyzed the difference of Tim-3 expression on T
cells between NCs and HBV-infected individuals. PBMCs from
all enrolled subjects (including 40 of NCs, 36 of AsC, and
40 of CHB) were stained and tested. Representative PBMC
samples from NC, AsC and CHB analyzed by flow cytometry was
shown in Figure 1A. PerCP-Cy5.5 Isotype control was used in
each analysis for the separation of Tim-3-positive and -negative
population. Elevated expression of Tim-3 on both CD4+ (6.41±
5.00%) and CD8+ (4.72 ± 3.98%) T cells was found in patients
with CHB in comparison with AsC (CD4+, 3.35 ± 2.22%, P =
0.034, Figure 1B; CD8+, 2.06 ± 1.63%, P = 0.021, Figure 1C)
and NC (CD4+, 3.32 ± 1.83%, P = 0.03, Figure 1B; CD8+, 2.28
± 0.94%, P = 0.049, Figure 1C).
Previous study demonstrated that HIV-1 viral products could
not directly induced Tim-3 expression on T cells (Mujib et al.,
2012). However, it was possible that the activity of HBV
viral products might differ due to strong immunogenicity of
HBV antigens. Thus, we then analyzed the Tim-3 expression
on CD4+ and CD8+ T cells in response to either HBV
antigens or peptides pool. Frequencies of Tim-3 expression
on unstimulated T cells from AsC and CHB, which were
presented in Figures 1B,C, were used as controls for further
analysis. Mixture of HBsAg, HBeAg, and HBcAg did not up-
regulate the expression of Tim-3 on T cells in either AsC
(P > 0.05, Figures 1D,E) and CHB (P > 0.05, Figures 1F,G).
Interestingly, HBV peptides pool could strongly induce increased
expression of Tim-3 on both CD4+ and CD8+ T cells, with
approximately elevation of 2.5-fold in AsC (CD4+, 8.77 ±
7.41%, P = 0.001, Figure 1D; CD8+, 5.44 ± 5.50%, P = 0.016;
Figure 1E) and 3.5-fold in CHB (CD4+, 21.33 ± 10.25%, P =
0.001, Figure 1F; CD8+, 11.16± 9.04%, P = 0.0001; Figure 1G).
There were no remarkable correlation between Tim-3 expression
on T cells and HBV DNA or ALT levels in CHB and AsC
(P > 0.05).
The Common γc Cytokines Drive Tim-3
Expression on CD4+ and CD8+ T Cells in
Patients with Chronic HBV Infection
The common γc cytokines were reported to robustly enhance
the Tim-3 expression on CD4+ and CD8+ T cells in HIV-1
infection (Mujib et al., 2012). Thus, PBMCs from 18 of AsC and
20 of CHB, which were selected from the above experiments,
were stimulated for 4 days with various common γc cytokines
(including IL-2, IL-7, IL-15, and IL-21), and Tim-3 expression
was analyzed on CD4+ and CD8+ T cells compared with cells
in plain medium alone in AsC (CD4+, 3.41 ± 2.03%, Figure 2A;
CD8+, 2.31± 1.70%, Figure 2C) and CHB (CD4+, 5.77± 4.20%,
Figure 2B; CD8+, 4.57 ± 3.83%, Figure 2D). Tim-3 expression
in response to common γc cytokines exhibited similar trends in
patients with AsC and CHB. CD4+ T cells stimulated with γc
cytokine IL-2 (AsC, 6.82 ± 5.85%, P = 0.0052; CHB, 10.67 ±
8.71%, P = 0.0062; compared with untreated cells), IL-7 (AsC,
4.52 ± 5.37%, P = 0.041; CHB, 10.54 ± 8.82%, P = 0.011),
and IL-21 (AsC, 6.28 ± 5.86%, P = 0.033; CHB, 10.58 ± 8.88%,
P = 0.008) presented remarkable elevated frequencies of Tim-
3+CD4+ T cells (Figures 2A,B). IL-15 stimulation significantly
increased the Tim-3+CD4+ T cells frequency in CHB patients
(10.92 ± 7.92%, P = 0.008; Figure 2B) but not in AsC patients
(5.85 ± 6.31%, P = 0.114; Figure 2A). CD8+ T cells stimulated
with IL-2 (AsC, 4.04 ± 3.48%, P = 0.008; CHB, 6.92 ± 5.23%,
P = 0.0039) and IL-15 (AsC, 4.30 ± 3.36%, P = 0.0036; CHB,
9.92 ± 6.43%, P = 0.0025) revealed notably increased Tim-
3+CD8+ T cells frequencies (Figures 2C,D). IL-7 stimulation
significantly elevated Tim-3 expression on CD8+ T cells in CHB
patients (6.60 ± 4.62%, P = 0.0032; Figure 2D) but not in AsC
patients (3.45 ± 3.15%, P = 0.250; Figure 2C). However, IL-
21 did not increase the frequencies of Tim-3+CD8+ T cells in
either AsC (3.22 ± 3.07%, P = 0.053; Figure 2C) and CHB
patients (6.33 ± 5.87%, P = 0.082; Figure 2D). Furthermore,
TCR-stimulated T cells via CD3/CD28 costimulation notably up-
regulated Tim-3 expression on both CD4+ (AsC, 6.83 ± 5.08%,
P = 0.001; CHB, 14.46 ± 7.47%, P < 0.0001) and CD8+ T
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FIGURE 1 | Tim-3 expression on CD4+ and CD8+ T cells in response to HBV-encoding antigens and HBV peptide pools. PBMCs from all enrolled subjects
(including 40 of NCs, 36 of AsC, and 40 of CHB) were stained and tested. (A) Representative flow plots of Tim-3+ cells within CD4+ and CD8+ T cells in normal
control (NC), asymptomatic HBV carrier (AsC), and chronic hepatitis B (CHB). PerCP-Cy5.5 Isotype control was used in each analysis for the separation of
Tim-3-positive and -negative population. Comparison of frequencies for CD4+Tim-3+ (B) and CD8+Tim-3+ cells (C) in NCs, AsC, and CHB. Thus, the frequencies
of Tim-3 expression on unstimulated T cells were used as controls for further studies. Comparison of frequencies for CD4+Tim-3+ (D) and CD8+Tim-3+ cells (E) in
response to HBV-encoding antigens and HBV peptide pools stimulations for 4 days in AsC. Comparison of frequencies for CD4+Tim-3+ (F) and CD8+Tim-3+ cells
(G) in response to HBV-encoding antigens and HBV peptide pools stimulations for 4 days in CHB. Data were presented as box-and-whisker plot. The box presented
as median and quartile, and the whisker plot presented as 2.5–97.5% percentile. Dunn’s multiple comparison test were used for comparison between groups.
cells (AsC, 4.52 ± 3.84%, P = 0.0015; CHB, 12.30 ± 7.29%,
P = 0.0015).
Common γc Cytokines Did Not Enhance
the Tim-3 Induction by Either
Anti-CD3/CD28 or HBV Peptides
Stimulation
The γc cytokines IL-2, IL-7, and IL-15 stimulation were more
potent inducers of Tim-3 on T cells and, thus, were used for
study further. We analyzed whether the γc cytokines presented
synergic effect to anti-CD3/CD38 or peptides stimulation on
Tim-3 expression on T cells. PBMC from 10 of AsC and 10 of
CHB patients, which were selected from the above experiments
of Figure 1 but did not overlap with the patients from Figure 2,
were cultured with anti-CD3/CD28, alone or presence of either
IL-2, IL-7, or IL-15. Tim-3 levels were assessed 4 days after
stimulation. The addition of γc cytokines IL-2, IL-7, or IL-15
costimulation with anti-CD3/CD28 did not result in an increased
frequencies of either Tim-3+CD4+ T cells (Figures 3A,C) or
Tim-3+CD8+ T cells (Figures 3B,D). Similar observations were
made with IL-15 and cells stimulated with HBV peptides pool.
Tim-3+CD8+ T cells frequencies did not elevated in response to
IL-15 and peptides costimulation in either AsC (7.17 ± 3.25%,
P = 0.912; Figure 3E) or CHB (9.06 ± 4.53%, P = 0.143;
Figure 3F).
Common γc Cytokines-Mediated Tim-3
Induction Could Not Be Abrogated by γc
Cytokine Receptor-Neutralizing Antibody
The γc cytokines increased Tim-3 expression on T cells
through the γ chain of the receptor in HIV-1 infection
(Mujib et al., 2012). We then further analyzed whether the
signaling through γ chain was also the pathway to regulate
Tim-3 expression in HBV infection. PBMCs from 8 of AsC
and 8 of CHB patients, which were selected from the above
experiments of Figure 1 but did not overlap with the patients
from Figure 2 or Figure 3, were cultured with anti-common
γc receptor neutralizing antibody at 10 µg/mL for 4 h, and
then γc cytokines, anti-CD3/CD8, as well as HBV peptides
were added for another 4 days treatment. Compared with
the PBMCs which did not receive γc-neutralizing antibody,
neither CD4+ nor CD8+ T cells displayed reduced frequencies
of Tim-3+ cells with each cytokine stimulation (P > 0.05,
Figure 4). There were consistent trends of reductions of Tim-
3 expression in AsC patients in response to IL-2 (CD4+, 4.98
± 2.40% to 3.62 ± 1.85%, P = 0.194, Figure 4A; CD8+, 3.49
± 1.98% to 2.53 ± 1.79%, P = 0.199, Figure 4C) and in
CHB patients in response to IL-7 (CD4+, 2.89 ± 0.74% to
1.94 ± 0.56%, P = 0.208, Figure 4B; CD8+, 5.13 ± 0.61% to
3.26 ± 0.65%, P = 0.051, Figure 4D), but these differences
failed to achieve significances. Moreover, both TCR-stimulated
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FIGURE 2 | Common γ-chain (γc) cytokine-mediated induction of Tim-3 expression in CD4+ and CD8+ T cells contained in peripheral blood
mononuclear cells (PBMCs). PBMCs were selected from 18 of AsC and 20 of CHB, which were used in the experiments of Figure 1. Total PBMCs were treated
with IL-2 (25 ng/mL), IL-7 (25 ng/mL), IL-15 (25 ng/mL), IL-21 (25 ng/mL), or anti-CD3/CD28 (1 µg/mL) for 4 days. Tim-3 expressions were assessed on CD4+ and
CD8+ T cells. (A) Comparison of frequencies for CD4+Tim-3+ cells in response to γc cytokine and anti-CD3/CD28 stimulations in AsC. (B) Comparison of
frequencies for CD4+Tim-3+ cells in response to γc cytokine and anti-CD3/CD28 stimulations in CHB. (C) Comparison of frequencies for CD8+Tim-3+ cells in
response to γc cytokine and anti-CD3/CD28 stimulations in AsC. (D) Comparison of frequencies for CD8+Tim-3+ cells in response to γc cytokine and
anti-CD3/CD28 stimulations in CHB. Data were presented as box-and-whisker plot. The box presented as median and quartile, and the whisker plot presented as
2.5–97.5% percentile. Dunn’s multiple comparison test were used for comparison between groups.
cells via anti-CD3/CD28 treatment and viral-specific cells via
HBV peptides stimulation were unaffected with regard to Tim-
3 frequencies, despite the addition of γc-neutralizing antibody
(P > 0.05, Figure 4).
We then further analyzed the phosphoylation of STAT-
1 in γc receptor-mediated signaling pathway. PBMCs were
selected from 10 of CHB patients which were enrolled in
Figure 1. As shown in Figure 5A, IL-15 stimulation significantly
increased the mean fluorescence intensity (MFI) value of
pSTAT-1(blue dashed line) in comparison with normal PBMCs
(purple dashed line) (P = 0.0007, Figure 5B). Importantly,
inhibition of γc receptor by neutralizing antibody significantly
reduced the phosphoylation of STAT-1 (red line) (P = 0.023,
Figure 5B), which confirmed the successful blockade of γc
receptor. Moreover, although MFI value of pSTAT-1 in IL-15
stimulated, γc receptor neutralized PBMCs (green line) was
reduced in comparison with IL-15 stimulated normal PBMCs
(P = 0.0027, Figure 5B), it is still remarkably elevated in
comparison of MFI value in γc receptor neutralized PBMCs (P
< 0.0001, Figure 5B).
DISCUSSION
In the present study, we provided the evidence to further
insight into the mechanism of Tim-3 regulation in chronic HBV
infection. We found a higher expression of Tim-3 on both
CD4+ and CD8+ T cells in patients with CHB compared to
NCs and AsC patients. This is consistent with the previous
notion that Tim-3 revealed a stepwise elevation with increasing
liver inflammation which was assessed by ALT levels (Nebbia
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FIGURE 3 | Induction of Tim-3 expression on T cells within PBMCs in response to common γ-chain (γc) cytokine plus antigens costimulation. PBMCs
were selected from 10 of AsC and 10 of CHB, which were used in the experiments of Figure 1 but did not overlap with the patients from Figure 2. Total PBMCs were
treated with IL-2 (25 ng/mL), IL-7 (25 ng/mL), IL-15 (25 ng/mL) plus anti-CD3/CD28 (1 µg/mL) or HBV peptide pools (10 µg/mL). Tim-3 expressions were assessed
on CD4+ and CD8+ T cells. (A) Comparison of frequencies for CD4+Tim-3+ cells in response to stimulation of γc cytokines and costimulation of γc cytokines
plus anti-CD3/CD28 in AsC. (B) Comparison of frequencies for CD4+Tim-3+ cells in response to stimulation of γc cytokines and costimulation of γc cytokines plus
anti-CD3/CD28 in CHB. (C) Comparison of frequencies for CD8+Tim-3+ cells in response to stimulation of γc cytokines and costimulation of γc cytokines
plus anti-CD3/CD28 in AsC. (D) Comparison of frequencies for CD8+Tim-3+ cells in response to stimulation of γc cytokines and costimulation of γc cytokines plus
anti-CD3/CD28 in CHB. (E) Comparison of frequencies for CD8+Tim-3+ cells in response to IL-15 stimulation and costimulation of IL-15 plus HBV peptide pools in
AsC. (F) Comparison of frequencies for CD8+Tim-3+ cells in response to IL-15 stimulation and costimulation of IL-15 plus HBV peptide pools in CHB. Data were
presented as box-and-whisker plot. The box presented as median and quartile, and the whisker plot presented as 2.5–97.5% percentile. Dunn’s multiple comparison
test were used for comparison between groups.
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FIGURE 4 | Induction of Tim-3 expression on T cells within PBMCs by common γ-chain (γc) cytokines (IL-2, IL-7, IL-15) could not be abrogated in the
presence of anti-common γc receptor neutralizing antibody compared with no antibody treatments. PBMCs were selected from 8 of AsC and 8 of CHB
patients, which were used in the experiments of Figure 1 but did not overlap with the patients from Figures 2, 3. (A) Comparison of frequencies for CD4+Tim-3+
cells in response to γc cytokines stimulation with or without neutralizing antibody in AsC. (B) Comparison of frequencies for CD4+Tim-3+ cells in response to γc
cytokines stimulation with or without neutralizing antibody in CHB. (C) Comparison of frequencies for CD8+Tim-3+ cells in response to γc cytokines stimulation with
or without neutralizing antibody in AsC. (D) Comparison of frequencies for CD8+Tim-3+ cells in response to γc cytokines stimulation with or without neutralizing
antibody in CHB. Data were presented as mean and standard deviation. Mann-Whitney test was used for comparison between groups. #P > 0.05.
et al., 2012). Although we did not find significant correlation
between Tim-3 expression and HBV DNA or ALT levels in HBV
infected individuals, both immunological and inflammatory
factors might contribute to the regulation of Tim-3 expression
in HBV infection.
HBV-encoding antigens were strong immunogens to activate
and stimulate immune cells. Thus, we postulated that soluble
HBV viral products could also induce Tim-3 expression.
The mixture of HBsAg, HBeAg, and HBcAg were used to
stimulate cultured PBMCs in vitro. However, Tim-3-expressing
CD4+ and CD8+ T cells did not elevated in response
to antigens in both AsC and CHB patients. Furthermore,
frequencies of Tim-3 expression were remarkably increased
in response to HBV peptide pools stimulation. This is partly
because that T cells recognized a peptide derived from the
foreign antigen bound to MHC molecule. However, HBV-
encoding antigens were unmodified native proteins with
different conformations, which did not expose the epitopes
recognized by MHC molecules. Moreover, direct stimulation
of TCR by anti-CD3/CD28 also notably increase Tim-3
expression on CD4+ and CD8+ T cells in both AsC and
CHB. Thus, Tim-3 expression in HBV-infected individuals
was partly an antigen-dependent manner as a result of
infection.
Previous studies have been demonstrated that Tim-3 could
also be up-regulated both dependently and independently of
TCR or antigenic stimulation in viral infection (Hastings et al.,
2009; Mujib et al., 2012). Mujib et al. (2012) revealed that Tim-3
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FIGURE 5 | Induction of phosphorylated STAT-1 in response to IL-15 stimulation in the presence of anti-common γc receptor neutralizing antibody.
PBMCs were selected from 10 of CHB patients which were enrolled in Figure 1. (A) Representative histogram of pSTAT-1 were shown. The light gray represented
isotype control. The purple dashed line represented untreated PBMCs. The blue dashed line represented IL-15 stimulated normal PBMCs. The red line represented γc
receptor neutralizing antibody treated PBMCs. The green line represented IL-15 stimulated, γc receptor neutralizing antibody treated PBMCs. (B) Comparison of
mean fluorescence intensity (MFI) value of pSTAT-1 among groups. The dashed line represented background levels from isotype control. Data were presented as
mean and standard deviation. Mann-Whitney test was used for comparison between groups.
could be upregulated in vitro in an inflammatory states where
enrichment of γc cytokines in HIV-1 infection. Our observation
that γc cytokines, specifically IL-2, IL-7, IL-15, and IL-21 were
potent inducers of Tim-3 expression on T cells in the antigen-
independent manner in HBV infection were consistent with the
role of these cytokines in HIV-1 infection (Mujib et al., 2012).
The elevations of γc cytokines were proved to be associated
with spontaneous viral clearance and HBeAg seroconversion
(He et al., 2013). γc cytokines predominantly related to
the regulation of lymphocyte development, homeostasis, and
functions (Overwijk and Schluns, 2009). IL-2 was a potent
inducer of T cell proliferation as well as Th1/Th2 differentiation
in inflammatory response (Hoyer et al., 2008). Both IL-7 and
IL-15 robustly expanded dendritic cell-activated HBV-specific
CD4+ T cells in vitro (Chen et al., 2006). Moreover, IL-15
was also important in the development and homeostasis of
memory CD8+ T cells, NK cells, and NKT cells (Villinger
et al., 2004). IL-15 also inhibited HBV replication via IFN-
β production and exerted anti-HBV functions independent of
γc receptor in mouse model (Yin et al., 2012). IL-21, which
derived from HBV-specific CD4+ T cells, played viral roles
in sustaining viral-specific CD8+ T cells and promoting B
cell response (Li et al., 2015), although our previous studies
showed that IL-21 did not enhance HBV-specific immune
response in mouse models (Zhang et al., 2014). Importantly,
high serum IL-21 levels after 12 weeks of telbivudine therapy
predicted HBeAg seroconversion in CHB (Ma et al., 2012).
Thus, the up-regulation of Tim-3 in response to γc cytokines(IL-
2, IL-7, IL-15, and IL-21) stimulation indicated that Tim-
3 may play a negative regulatory role in response to these
cytokines, which were consistent with the previously proposed
roles of Tim-3 expression on T cells (Sakuishi et al., 2011;
Mujib et al., 2012). Although γc cytokines were considered
as proinflammation, the involvement of these cytokines in
up-regulation of Tim-3 suggested that they were also responsible
for activation of inhibitory pathway in viral infections (Mujib
et al., 2012). Furthermore, cells costimulated with γc cytokines
plus anti-CD3/CD28 or HBV peptides did not result in
greater Tim-3 induction compared with mono-stimulation,
which suggested that the antigen-dependent and independent
induction did not reveal synergic effects in Tim-3 regulation
and these two pathways individually were sufficient for Tim-3
induction.
We were not able to diminished γc cytokines-induced
Tim-3 elevation on T cells by anti-common γc receptor
neutralizing antibody in patients with chronic HBV infection.
γc cytokines shared γc receptor usage and signal through
specific heterodimeric or trimeric receptor complexes (Toe et al.,
2013). The consequences of cognate receptor engagement were
dependent on receptor expression patterns, expression levels, and
downstream JAK-STAT signaling components (Toe et al., 2013).
Thus, downregulation of phosphorylated STAT-1 demonstrated
successful blockade of γc receptor. The neutralizing antibody
might only partly block the function of common γc receptor.
However, other components of the receptor complex might play
important roles in γc cytokines-induced Tim-3 expression. This
was partly because that IL-15 stimulation could also increase the
pSTAT-1 level in γc receptor-inhibited PBMCs. Other possibility
could be that γc receptor neutralizing antibody caused a shift in
the functional status of Tim-3+ T cells. Moreover, γc cytokines
might also modulate Tim-3 expression through other signaling
pathways. Thus, further studies were needed to investigate the
STAT phosphorylation and the changes of Tim-3 expression
by functional blocking the other component of receptor
complex.
In conclusion, both HBV peptides and γc cytokines induced
the up-regulation of Tim-3, which suggested that elevation
of Tim-3 expression on T cells could be regulated by both
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8 March 2017 | Volume 7 | Article 98
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antigen-dependent and independent manner in patients with
chronic HBV infection. The role of γc cytokines in modulation
of inhibitory pathway could be evaluated as immnotherapies in
humans.
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